News

Pharmaceutical Technology6h
Prasad’s FDA exit may accelerate cell and gene therapy approvals
Analysts say the departure of the CBER head may alleviate overhang in the cell and gene therapy space. Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and ...
Vinay Prasad’s ouster leaves biotech guessing at FDA direction
The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and ...
PharmExec7h
Vinay Prasad’s FDA Departure Follows Controversy Over Drug Rejections
The FDA’s top vaccine and gene therapy official resigned amid heightened scrutiny over recent drug approval decisions and ...
BioSpace7h
Exit Stage Right: With Prasad Out, Analysts Hope for More Traditional Replacement
As analysts parsed news of Vinay Prasad’s ouster, worries over drug approval delays, cell and gene therapy impacts and more ...